Cover Image
市場調查報告書

亞太地區的骨質疏鬆症治療藥市場

Osteoporosis Drugs Market in the APAC Region 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 320962
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
亞太地區的骨質疏鬆症治療藥市場 Osteoporosis Drugs Market in the APAC Region 2015-2019
出版日期: 2014年12月03日 內容資訊: 英文 73 Pages
簡介

骨質疏鬆症由於沒有特別症狀,往往到骨折後才判明。這個疾病的風險要素為,老齡化,性荷爾蒙的減少和更年期,抽煙等。亞太地區骨質疏鬆症治療藥市場從2014年到2019年的CAGR(年複合成長率)預計為4.73%。

本報告提供亞太地區骨質疏鬆症治療藥市場現狀及今後的成長預測分析、開發平台概要、各類藥物趨勢、主要治療藥的評估、市場發展要素與課題、主要供應商分析等

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品
    • 產品簡介

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 開發平台概要

第8章 流行病學和人口統計

  • 中國
  • 香港
  • 日本
  • 印度

第9章 各類藥物的市場區隔

第10章 主要醫藥品的市場評估

  • Prolia
  • Fosamax
  • Evista
  • Forteo
  • Zometa

第11章 購買標準

第12章 市場成長因素

第13章 成長因素與其影響

第14章 市場課題

第15章 成長因素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他卓越供應商

第19章 主要供應商分析

  • Amgen
  • Eli Lilly
  • Merck & Co. Inc.
  • Novartis AG

第20章 相關報告

目錄
Product Code: IRTNTR4777

About Osteoporosis

Osteoporosis is a disease that reduces of the mass and density of bone, and results in increased risk of fracture. In this disease, the risks related to fracture increases because of the increased permeability of the bones. Often, there are no symptoms observed until the first fracture occurs. Increase in age, low body weight, low sex hormones or menopause, and smoking are some of the risk factors associated with this disease.

TechNavio's analysts forecast the Osteoporosis Drugs market in APAC to grow at a CAGR of 4.73 percent over the period 2014-2019.

Covered in this Report

The Osteoporosis Drugs market in APAC can be divided into two segments: Antiresorptives and Anabolics. This report covers the present scenario and the growth prospects of the Osteoporosis Drugs market in APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various osteoporosis drugs that are available in the market.

TechNavio's report, the Osteoporosis Drugs market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Osteoporosis Drugs market in APAC landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors

  • Amgen
  • Eli Lilly
  • Merck
  • Novartis

Other Prominent Vendors

  • F. Hoffmann La Roche
  • GlaxoSmithKline
  • Jiangsu Hengrui Medicine
  • Pfizer Inc.
  • Qingdao Chiatai Haier Pharmaceutical  

Market Driver

  • Increasing Global Aging Population
  • For a full, detailed list, view our report

Market Challenge

  • Multiple Patent Expiries
  • For a full, detailed list, view our report

Market Trend

  • Increasing Awareness of Bone Health Education
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Pipeline Snapshot

08. Epidemiology and Demography

    • 08.1.1. China
    • 08.1.2. Hong Kong
    • 08.1.3. Japan
    • 08.1.4. India

09. Market Segmentation by Drug Class

10. Market Assessment of Top Drugs

  • 10.1. Prolia
    • 10.1.1. Sales
  • 10.2. Fosamax
    • 10.2.1. Sales
  • 10.3. Evista
    • 10.3.1. Sales
  • 10.4. Forteo
    • 10.4.1. Sales
  • 10.5. Zometa
    • 10.5.1. Sales

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

  • 18.1. Competitive Scenario
    • 18.1.1. Key News
    • 18.1.2. Mergers and Acquisitions
  • 18.2. Market Share Analysis 2013
  • 18.3. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Amgen
    • 19.1.1. Key Facts
    • 19.1.2. Business Overview
    • 19.1.3. Business Segmentation by Revenue 2013
    • 19.1.4. Product Portfolio by Revenue 2013
    • 19.1.5. Business Segmentation by Revenue 2012 and 2013
    • 19.1.6. Geographical Segmentation by Revenue 2013
    • 19.1.7. Business Strategy
    • 19.1.8. Recent Developments
    • 19.1.9. SWOT Analysis
  • 19.2. Eli Lilly
    • 19.2.1. Key Facts
    • 19.2.2. Business Overview
    • 19.2.3. Business Segmentation by Revenue
    • 19.2.4. Sales by Geography
    • 19.2.5. Business Strategy
    • 19.2.6. Key Information
    • 19.2.7. SWOT Analysis
  • 19.3. Merck & Co. Inc.
    • 19.3.1. Key Facts
    • 19.3.2. Business Overview
    • 19.3.3. Business Segmentation by Revenue 2013
    • 19.3.4. Business Segmentation by Revenue 2012 and 2013
    • 19.3.5. Sales by Geography
    • 19.3.6. Business Strategy
    • 19.3.7. Key Developments
    • 19.3.8. SWOT Analysis
  • 19.4. Novartis AG
    • 19.4.1. Key Facts
    • 19.4.2. Business Description
    • 19.4.3. Business Segmentation
    • 19.4.4. Revenue by Business Segmentation
    • 19.4.5. Revenue Comparison 2012 and 2013
    • 19.4.6. Sales by Geography
    • 19.4.7. Business Strategy
    • 19.4.8. Key Developments
    • 19.4.9. SWOT Analysis

20. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Osteoporosis Drugs Market in APAC 2013-2018 (US$ billion)
  • Exhibit 3: Clinical Trial Map of Conjugated Estrogens/Bazedoxifene
  • Exhibit 4: Clinical Trial Map of Viviant
  • Exhibit 5: Clinical Trial Map of Prolia
  • Exhibit 6: Clinical Trial Map of Romosozumab
  • Exhibit 7: Clinical Trial Map of LY2541546 (Blosozumab)
  • Exhibit 8: Population Increase in People Aged 50 Years Or Over By Country (million), 2013 to 2019
  • Exhibit 9: Osteoporosis Drugs Market in APAC Segmentation by Drug Class
  • Exhibit 10: Antiresorptives Drugs Segmentation
  • Exhibit 11: Bisphosphonates Drugs Segmentation
  • Exhibit 12: Amgen's Prolia Global Revenue 2010-2013 (US$ million)
  • Exhibit 13: Merck's Fosamax Global Revenue 2009-2012 (US$ million)
  • Exhibit 14: Eli Lilly's Evista Global Revenue 2010-2013 (US$ million)
  • Exhibit 15: Eli Lilly's Forteo Global Revenue 2010-2013 (US$ million)
  • Exhibit 16: Novartis Zometa Global Revenue 2010-2013 (US$ million)
  • Exhibit 17: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 18: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 19: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 20: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 21: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 22: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 23: Eli Lilly: Sales by Geography 2013
  • Exhibit 24: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 25: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 26: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 27: Novartis AG: Business Segmentation
  • Exhibit 28: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 29: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 30: Novartis AG: Revenue by Geographical Segmentation 2013
Back to Top